The North America Cardiac Marker Testing Market is experiencing significant growth, driven by a rising prevalence of cardiovascular diseases, advancements in diagnostic technology, and increasing healthcare expenditure. The market size was valued at USD 2,830 Million in 2025 and is projected to reach USD 5,920 Million by 2035, expanding at a CAGR of 6.7% from 2024 to 2035.
The economic impact of tariffs on "North America Cardiac Marker Testing Market".
Market Growth Drivers
Increasing Prevalence of Cardiovascular Diseases: The surge in the incidence of cardiovascular diseases (CVD) such as coronary artery disease and heart failure in North America directly drives the demand for cardiac marker testing. According to the American Heart Association, heart disease remains the leading cause of death in the United States, with over 800,000 cases annually. Companies like Abbott Laboratories have expanded their cardiac marker assay portfolios to cater to the growing demand in emergency departments and clinical laboratories, providing rapid, reliable diagnostic results for early intervention.
Technological Advancements and Automation in Diagnostics: The adoption of next-generation point-of-care (POC) testing devices, high-sensitivity assays, and integration of artificial intelligence in diagnostic workflows have greatly improved testing accuracy and turnaround times. Roche Diagnostics, for instance, introduced high-sensitivity troponin assays, supporting faster diagnosis of myocardial infarctions. These innovations reduce hospitalization time and enhance patient outcomes, fueling market growth.
Market Trends
Shift Towards Point-of-Care Testing: The trend towards decentralized healthcare has led to growing utilization of point-of-care (POC) cardiac marker testing. This allows for immediate diagnosis in ambulances, urgent care clinics, and rural settings, bypassing delays associated with central laboratory testing. Companies like QuidelOrtho have introduced compact, easy-to-use cardiac biomarker analyzers facilitating quicker triage and treatment decisions.
Integration of AI and Data Analytics: Leading market players such as Siemens Healthineers are leveraging AI-powered data analytics to improve interpretation of cardiac marker test results. AI-based platforms help clinicians distinguish between acute coronary syndromes and non-cardiac chest pain with higher precision. This integration enhances clinical decision-making and optimizes resource allocation in hospitals and healthcare facilities.
Market Opportunity
Expansion into Home-Based Testing: With the surge in telehealth and remote patient monitoring, companies like Abbott have an opportunity to develop and market home-based cardiac marker tests, offering convenience and timely health monitoring for at-risk patients.
Growing Strategic Collaborations: Collaborations between diagnostic companies and healthcare providers, such as strategic partnerships between Beckman Coulter and hospital networks, offer opportunities to expand the reach of innovative cardiac testing solutions and improve patient access.
North America Cardiac Marker Testing Market Revenue (USD Million), 2020-2035
The revenue chart illustrates consistent growth in the North America Cardiac Marker Testing Market over the period 2020 to 2035. Starting at USD 1,750 Million in 2020, the market exhibits a steady upward trend, reaching USD 2,830 Million by 2025 and anticipated to more than double to USD 5,920 Million by 2035. This growth is propelled by technological innovation, increased adoption of POC testing, and higher CVD rates. The chart underscores the resilience and expansion potential of the market within the forecast period.
North America Cardiac Marker Testing Market by Region Share (%), 2025
The pie chart for 2025 shows that the United States dominates the North America Cardiac Marker Testing Market with a 68% share, followed by Canada at 22%, and Mexico at 7%. Central America and the Caribbean collectively account for the remaining 3%. This regional distribution reflects advanced healthcare infrastructure and higher adoption rates in the US and Canada, while emerging markets in Mexico and the Caribbean are gradually increasing their market penetration thanks to investments in healthcare modernization.
Recent Developments
In May 2024, Abbott announced FDA clearance for its next-generation high-sensitivity troponin I assay, aimed at early detection of myocardial infarction. The new product expands Abbott's POC testing capabilities and enhances clinical workflow efficiency, supporting hospitals and clinics in managing cardiovascular emergencies more effectively.
In March 2024, QuidelOrtho launched the Sofia Q rapid cardiac biomarker analyzer across key North American healthcare networks. The device provides results within minutes for multiple cardiac markers, increasing adoption among emergency departments and improving patient throughput in acute care settings.
In February 2024, Roche Diagnostics entered into a strategic collaboration with a major US hospital network to integrate AI-driven cardiac risk assessment modules into routine diagnostic protocols. This partnership aims to enhance decision support tools for emergency physicians and cardiologists, optimizing diagnosis and resource allocation.
Press Releases